The European Medicines Agency (EMA) has approved the use of the Pfizer-BioNTech COVID-19 vaccine for children aged 12 to 15 years. The Pfizer BioNotech vaccine was first approved in the European Union of 27 member states and in December was granted a license to apply to people 16 years of age or older. Addressing a press conference here on Friday, EMA’s vaccine strategy manager, Marco Cavaleri, said that the EU regulator had found the necessary data to approve the use of vaccines for children and adolescents and data. This shows that it is highly effective against Covid-19.
He said the decision needed to be approved by the European Commission and regulators from different countries would have to decide whether children under 16 would be vaccinated. Regulators in Canada and the US had already recommended its use for adolescents. The EMA reported that a study based on more than 2,200 adolescents in the US showed that the vaccine is safe and effective. Testing showed that the immune response in this group was comparable in the 16–25 age group. The study suggests that the vaccine was effective in preventing Covid.
The EMA said in its statement, ‘The vaccine was found to be quite safe and the vaccine’s side effects were the same as those seen in adults aged 16 years or older, even in the 12-15 age group and there is nothing to worry about.’ People of this age group may also feel pain, fatigue, headache, muscle and joint pain, chills, and fever after getting vaccinated.